NewAmsterdam Pharma (NAMS) Stock Overview
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NAMS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.29 |
| 52 Week High | US$41.47 |
| 52 Week Low | US$14.06 |
| Beta | 0.027 |
| 1 Month Change | 36.05% |
| 3 Month Change | 53.75% |
| 1 Year Change | 92.39% |
| 3 Year Change | 261.76% |
| 5 Year Change | n/a |
| Change since IPO | 235.98% |
Recent News & Updates
Rainbows and Unicorns: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Became A Lot More Optimistic
Aug 18
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14%
Jun 10Recent updates
Rainbows and Unicorns: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Became A Lot More Optimistic
Aug 18NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14%
Jun 10Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation
May 29Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report
May 13NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib
Mar 01Companies Like NewAmsterdam Pharma (NASDAQ:NAMS) Are In A Position To Invest In Growth
Feb 27Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies
Oct 04Will NewAmsterdam Pharma (NASDAQ:NAMS) Spend Its Cash Wisely?
Oct 01NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 03Shareholder Returns
| NAMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | -0.01% | 1.3% |
| 1Y | 92.4% | 2.0% | 16.7% |
Return vs Industry: NAMS exceeded the US Biotechs industry which returned 2.6% over the past year.
Return vs Market: NAMS exceeded the US Market which returned 16.6% over the past year.
Price Volatility
| NAMS volatility | |
|---|---|
| NAMS Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NAMS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NAMS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 77 | Michael Davidson | www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
| NAMS fundamental statistics | |
|---|---|
| Market cap | US$3.94b |
| Earnings (TTM) | -US$165.71m |
| Revenue (TTM) | US$64.01m |
Is NAMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAMS income statement (TTM) | |
|---|---|
| Revenue | US$64.01m |
| Cost of Revenue | US$0 |
| Gross Profit | US$64.01m |
| Other Expenses | US$229.72m |
| Earnings | -US$165.71m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -258.91% |
| Debt/Equity Ratio | 0% |
How did NAMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/23 08:02 |
| End of Day Share Price | 2025/10/23 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NewAmsterdam Pharma Company N.V. is covered by 17 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Geoffrey Meacham | Citigroup Inc |
| Asad Haider | Goldman Sachs |